Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BEAM NASDAQ:DNLI NASDAQ:ORIC NASDAQ:TNGX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBEAMBeam Therapeutics$29.03-1.3%$29.41$15.60▼$36.44$3.03B2.251.82 million shs1.59 million shsDNLIDenali Therapeutics$21.66+3.0%$19.80$12.58▼$23.77$3.34B1.031.80 million shs2.18 million shsORICOric Pharmaceuticals$8.27+5.8%$9.03$7.23▼$14.93$809.51M1.041.65 million shs1.56 million shsTNGXTango Therapeutics$30.94+3.8%$23.46$4.40▼$32.79$4.31B1.194.43 million shs9.96 million shsMissed the SpaceX IPO? Buy These 7 Stocks InsteadThe space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBEAMBeam Therapeutics-0.27%-10.44%-6.87%+16.89%+64.39%DNLIDenali Therapeutics+1.99%+4.37%+8.02%+2.19%+38.38%ORICOric Pharmaceuticals+3.71%-2.49%-11.44%-34.29%-16.72%TNGXTango Therapeutics+3.97%+34.63%+26.89%+72.37%+529.11%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBEAMBeam Therapeutics$29.03-1.3%$29.41$15.60▼$36.44$3.03B2.251.82 million shs1.59 million shsDNLIDenali Therapeutics$21.66+3.0%$19.80$12.58▼$23.77$3.34B1.031.80 million shs2.18 million shsORICOric Pharmaceuticals$8.27+5.8%$9.03$7.23▼$14.93$809.51M1.041.65 million shs1.56 million shsTNGXTango Therapeutics$30.94+3.8%$23.46$4.40▼$32.79$4.31B1.194.43 million shs9.96 million shsMissed the SpaceX IPO? Buy These 7 Stocks InsteadThe space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBEAMBeam Therapeutics-0.27%-10.44%-6.87%+16.89%+64.39%DNLIDenali Therapeutics+1.99%+4.37%+8.02%+2.19%+38.38%ORICOric Pharmaceuticals+3.71%-2.49%-11.44%-34.29%-16.72%TNGXTango Therapeutics+3.97%+34.63%+26.89%+72.37%+529.11%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBEAMBeam Therapeutics 2.71Moderate Buy$46.8361.08% UpsideDNLIDenali Therapeutics 2.87Moderate Buy$34.2558.44% UpsideORICOric Pharmaceuticals 2.76Moderate Buy$18.92128.10% UpsideTNGXTango Therapeutics 2.71Moderate Buy$38.4224.14% UpsideCurrent Analyst Ratings BreakdownLatest ORIC, DNLI, BEAM, and TNGX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/12/2026ORICOric Pharmaceuticals Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$14.006/9/2026TNGXTango Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$27.00 ➝ $66.006/9/2026TNGXTango Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$30.00 ➝ $42.006/8/2026TNGXTango Therapeutics MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$36.006/8/2026TNGXTango Therapeutics Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetPeer Perform ➝ Outperform$35.006/8/2026TNGXTango Therapeutics B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/8/2026ORICOric Pharmaceuticals BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/8/2026ORICOric Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.006/8/2026TNGXTango Therapeutics Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$55.00 ➝ $69.006/8/2026TNGXTango Therapeutics Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradePeer Perform ➝ Outperform5/28/2026TNGXTango Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBEAMBeam Therapeutics$139.74M21.40N/AN/A$12.20 per share2.38DNLIDenali Therapeutics$330.53M10.38N/AN/A$6.91 per share3.13ORICOric PharmaceuticalsN/AN/AN/AN/A$3.90 per shareN/ATNGXTango Therapeutics$56.99M78.54N/AN/A$2.57 per share12.04Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBEAMBeam Therapeutics-$79.99M-$0.68N/AN/AN/A-39.66%-29.00%-22.61%8/4/2026 (Estimated)DNLIDenali Therapeutics-$512.54M-$2.88N/AN/AN/AN/A-52.20%-43.86%8/10/2026 (Estimated)ORICOric Pharmaceuticals-$129.47M-$1.44N/AN/AN/AN/A-35.33%-33.31%8/11/2026 (Estimated)TNGXTango Therapeutics-$101.59M-$0.83N/AN/AN/A-151.15%-41.54%-33.44%8/4/2026 (Estimated)Latest ORIC, DNLI, BEAM, and TNGX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026TNGXTango Therapeutics-$0.32-$0.32N/A-$0.32$0.58 millionN/A5/7/2026Q1 2026BEAMBeam Therapeutics-$1.0278-$0.91+$0.1178-$0.91$10.98 million$31.74 million5/7/2026Q1 2026DNLIDenali Therapeutics-$0.73-$0.69+$0.04-$0.69$2.57 millionN/A5/4/2026Q1 2026ORICOric Pharmaceuticals-$0.31-$0.34-$0.03-$0.34N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBEAMBeam TherapeuticsN/AN/AN/AN/AN/ADNLIDenali TherapeuticsN/AN/AN/AN/AN/AORICOric PharmaceuticalsN/AN/AN/AN/AN/ATNGXTango TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBEAMBeam Therapeutics0.0916.9916.99DNLIDenali Therapeutics0.019.289.28ORICOric PharmaceuticalsN/A16.3316.33TNGXTango TherapeuticsN/A27.3827.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBEAMBeam Therapeutics99.68%DNLIDenali Therapeutics92.92%ORICOric Pharmaceuticals95.05%TNGXTango Therapeutics78.99%Insider OwnershipCompanyInsider OwnershipBEAMBeam Therapeutics3.80%DNLIDenali Therapeutics12.50%ORICOric Pharmaceuticals5.70%TNGXTango Therapeutics6.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBEAMBeam Therapeutics510102.88 million98.97 millionOptionableDNLIDenali Therapeutics430158.71 million138.87 millionOptionableORICOric Pharmaceuticals80103.52 million97.62 millionOptionableTNGXTango Therapeutics90144.65 million135.25 millionOptionableORIC, DNLI, BEAM, and TNGX HeadlinesRecent News About These CompaniesIs Tango Therapeutics (TNGX) Price Justified After Its 7x Surge In One YearJune 10 at 8:15 PM | finance.yahoo.comTango Therapeutics Announces Major Underwritten Equity OfferingJune 10 at 7:10 PM | tipranks.comTango Therapeutics Announces Pricing of $600 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsJune 9 at 11:11 PM | quiverquant.comQTango Therapeutics Announces Pricing of $600 Million Upsized Public OfferingJune 9 at 10:49 PM | globenewswire.comTango Therapeutics: Combo Data With Revolution's RAS Inhibitor Whets Risk AppetiteJune 9 at 3:10 PM | seekingalpha.comTango Therapeutics (TNGX) stock soars on pancreatic cancer trial resultsJune 9 at 2:51 PM | msn.comTNGX Stock Jumps 53% on Early Pancreatic Cancer Study ResultsJune 9 at 1:46 PM | zacks.comTango shares surge on early pancreatic cancer combination dataJune 9 at 9:51 AM | thepharmaletter.comTTango Therapeutics, Inc. (TNGX) Discusses Promising Clinical Results for Vopimetostat and Pan-RAS Inhibitor Combination in MTAP-Deleted Pancreatic Cancer TranscriptJune 8, 2026 | seekingalpha.comTango Therapeutics stock soars on promising pancreatic cancer dataJune 8, 2026 | invezz.comITango Therapeutics Announces Proposed $500 Million Public OfferingJune 8, 2026 | globenewswire.comTango Therapeutics, Inc. (TNGX) Discusses Promising Clinical Results for Vopimetostat and Pan-RAS Inhibitor Combination in MTAP-Deleted Pancreatic Cancer - SlideshowJune 8, 2026 | seekingalpha.comTango Therapeutics stock soars on promising pancreatic cancer dataJune 8, 2026 | invezz.comIStock Movers: Intel, Tango Therapeutics, StrategyJune 8, 2026 | bloomberg.comTNGX stock hits all-time high – Wolfe Research calls Tango Therapeutic’s pancreatic cancer trial data ‘groundbreaking’June 8, 2026 | msn.comTango Therapeutics Stock Soars 42% After 'Unprecedented' Data on Pancreatic Cancer TreatmentJune 8, 2026 | barrons.comTango skyrockets 47% on eye-popping pancreatic cancer resultsJune 8, 2026 | msn.comTango Therapeutics' pancreatic cancer drug combo shows promise in studyJune 8, 2026 | reuters.comTango Therapeutics Reports Encouraging Initial Phase 1/2 Data on Vopimetostat and Daraxonrasib Combination for Treatment of MTAP-Deleted Pancreatic CancerJune 8, 2026 | quiverquant.comQTango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic CancerJune 8, 2026 | globenewswire.comVanguard Group Inc. Has $59.81 Million Holdings in Tango Therapeutics, Inc. $TNGXMay 15, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX IPO: Opportunity? Or the Ultimate Hype Trade?By Chris Markoch | May 22, 2026The Great SPR Arbitrage: An Oil Market Glitch Fuels Sector GainsBy Jeffrey Neal Johnson | May 14, 2026Aggressive Insider Buying Signals Opportunity in 3 Risky StocksBy Thomas Hughes | June 2, 2026From Runway to Riches: Victoria's Secret's New LookBy Jeffrey Neal Johnson | June 4, 2026The Great AI Rotation: Cashing In on DataBy Jeffrey Neal Johnson | May 20, 2026ORIC, DNLI, BEAM, and TNGX Company DescriptionsBeam Therapeutics NASDAQ:BEAM$29.03 -0.38 (-1.29%) Closing price 04:00 PM EasternExtended Trading$29.38 +0.34 (+1.19%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.Denali Therapeutics NASDAQ:DNLI$21.66 +0.64 (+3.04%) Closing price 04:00 PM EasternExtended Trading$21.66 0.00 (0.00%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.Oric Pharmaceuticals NASDAQ:ORIC$8.27 +0.45 (+5.75%) Closing price 04:00 PM EasternExtended Trading$7.72 -0.55 (-6.59%) As of 06:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.Tango Therapeutics NASDAQ:TNGX$30.94 +1.12 (+3.76%) Closing price 04:00 PM EasternExtended Trading$30.82 -0.12 (-0.38%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
